No, I think not. Copious genomic info but very very little wrt the huge number of possible antigens. Many pharmaceutical companies have data here, but that's proprietary. But even in aggregate, if possible, that's a "drop in the bucket". Maybe useful, but still a drop in the bucket. And even then, if aggregated, perhaps useful in some cases. But go through clinical testing, and you're still talking about ~10 years before anything is proven.
If "cure cancer" is do-able via ML, its still DECADES away. IF.
If "cure cancer" is do-able via ML, its still DECADES away. IF.